High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in high‐grade cervical intraepithelial neoplasia, adenocarcinoma in… compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
High‐grade cervical, vulval, and vaginal disease · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in high‐grade cervical, vulval, and vaginal disease at up to 4.5‐year compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
Overall systemic events and general symptoms · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in overall systemic events and general symptoms at 15‐day compared with quadrivalent HPV vaccine (moderate certainty).
1 finding from 1 review
Serious adverse events at up to 4.5‐year · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in serious adverse events at up to 4.5‐year compared with quadrivalent HPV vaccine (low certainty).
1 finding from 1 review
High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at up to 4.5‐year · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine showed no clear difference in mortality at up to 4.5‐year compared with quadrivalent HPV vaccine (low certainty).
1 finding from 1 review
High‐grade cervical, vulval, and vaginal disease · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall systemic events and general symptoms · 9‐ to 15‐year‐old females
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at up to 5‐year · 9‐ to 15‐year‐old females
It is very uncertain whether two doses of HPV vaccine changes serious adverse events at up to 5‐year compared with three doses of HPV vaccine (very low certainty).
1 finding from 1 review
Mortality at up to 5‐year · 9‐ to 15‐year‐old females
Two doses of HPV vaccine showed no clear difference in mortality at up to 5‐year compared with three doses of HPV vaccine (low certainty).
1 finding from 1 review
Clinical and harms outcomes* · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HCP used 'open questions' · Healthcare professionals working with people who have cancer
1 finding from 1 review
Elicited concerns · Healthcare professionals working with people who have cancer
1 finding from 1 review
Gave appropriate information · Healthcare professionals working with people who have cancer
1 finding from 1 review
Empathy · Healthcare professionals working with people who have cancer
1 finding from 1 review
Gave facts only · Healthcare professionals working with people who have cancer
1 finding from 1 review
Emotional exhaustion: Maslach Burnout Inventory: · Healthcare professionals working with people who have cancer
1 finding from 1 review
Anxiety · Healthcare professionals working with people who have cancer
1 finding from 1 review